Cayston (aztreonam for inhalation solution)
An approved treatment for Cystic Fibrosis.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify Aztreonam for inhalation solution wherever you encounter it, plus the key facts at a glance.
- Generic name
- Aztreonam for inhalation solution
- Brand name
- Cayston
- Development code
- AZLI
- Drug class
- Monobactam antibiotic (inhaled)
- Manufacturer
- Gilead Sciences, Inc.
- How it's taken
- Inhaled through the Altera nebulizer, 3 times a day for 28 days, then 28 days off
An antibiotic breathed in through the Altera nebulizer 3 times a day for 28 days, then stopped for 28 days, for people with cystic fibrosis who have Pseudomonas aeruginosa bacteria in their lungs[1].
- Cayston is approved to improve breathing symptoms in these patients, and the FDA first approved it on February 22, 2010[1][2].
- The label says safety and effectiveness have not been established in children under 7, in people whose FEV1 is below 25% or above 75% of predicted, or in people colonized with Burkholderia cepacia[1]. Its label has no boxed warning[1].
We'll email you when Cayston's FDA label changes, when the FDA acts on it, and when new trials for Cystic Fibrosis open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where Aztreonam for inhalation solution fits
Cayston (aztreonam) is an inhaled antibiotic approved since 2010 for people with cystic fibrosis who have Pseudomonas aeruginosa in their lungs, taken in 28-day courses with 28 days off to improve breathing symptoms[1][2].
- Standard cystic fibrosis care pairs airway clearance and mucus-thinning drugs such as Pulmozyme (dornase alfa) with CFTR modulators such as Trikafta, which treat the faulty protein itself for people 2 and older with a responsive CFTR variant[10][11].
- TOBI (tobramycin inhalation solution) is the other inhaled antibiotic on the FDA-approved list for cystic fibrosis with Pseudomonas, labeled for people 6 and older[9].
- Cayston's label sets 7 as the lowest age studied, and both labels leave out people with FEV1 below 25% or above 75% of predicted and people colonized with Burkholderia cepacia[1][9].
- One open-label Phase 3 trial sponsored by Gilead compared the 2 drugs directly over 3 on and off courses in 273 people 6 and older[5][8].
- The authors reported that lung function improved more on Cayston than on tobramycin solution, with fewer hospital stays for breathing problems, in a trial where patients and doctors knew which drug was given (Assael and colleagues, Journal of Cystic Fibrosis, 2013)[5].
- The Cayston label itself describes only its placebo-controlled trial and makes no comparison with TOBI[1].
- Anyone with Pseudomonas in their sputum can ask their CF care team whether an inhaled antibiotic fits alongside their CFTR modulator, which one suits their age and lung function, and how the 28-day on and off cycle fits their other daily treatments.
How Aztreonam for inhalation solution works
Many people with cystic fibrosis carry Pseudomonas aeruginosa, a bacterium that settles in the thick mucus of the airways and keeps coming back. Aztreonam is an antibiotic that attacks Gram-negative bacteria such as Pseudomonas, according to the Cayston label[1]. Aztreonam binds penicillin-binding proteins, which the bacteria use to build their cell walls, and that stops the wall from forming and kills the cell[1].
The label says aztreonam keeps working in the presence of cystic fibrosis lung secretions[1]. Aztreonam belongs to the monobactams, whose single-ring core is built differently from penicillins, cephalosporins and carbapenems, the beta-lactam antibiotics[1]. Breathing it in puts the drug where the bacteria live. Sputum held an average of 726mcg/g of aztreonam 10 minutes after the first 75mg dose, while blood levels peaked near 0.59mcg/mL, against about 54mcg/mL after a 500mg injection[1].
About 10% of an inhaled dose leaves the body unchanged in urine, and the half-life in blood is about 2.1 hours[1]. Cayston treats the infection and does not change the faulty CFTR protein that causes cystic fibrosis.
Side effects and safety
- Allergy to aztreonam. Cayston is not used in anyone with a known allergy to aztreonam
- Allergic reactions. facial rash, facial swelling and throat tightness were reported in trials, and severe allergic reactions have followed injected aztreonam in people with no known history of exposure to aztreonam; the label says to stop Cayston if an allergic reaction occurs
- Beta-lactam allergy. the label advises caution in people with a history of allergy to penicillins, cephalosporins or carbapenems because cross-reactivity may occur, though people with a known beta-lactam allergy received Cayston in trials with no severe allergic reactions reported
- Bronchospasm. sudden airway tightening can follow nebulized drugs; a drop in FEV1 of 15% or more right after a dose, despite a bronchodilator first, was seen in 3% of patients on Cayston, and the label says to stop treatment if chest tightness develops during nebulizer use
- FEV1 drop after the 28-day course. patients whose FEV1 rose during a course were sometimes treated for a lung flare when FEV1 fell afterward, so the label asks doctors to compare with the FEV1 measured before Cayston
- Drug-resistant bacteria. used without a known Pseudomonas aeruginosa infection, Cayston is unlikely to help and raises the risk of resistant bacteria
- FEV1 measured before Cayston is started, so later changes can be judged against it
- Confirmation that Pseudomonas aeruginosa is in the lungs before treatment
- The Altera Nebulizer System checked before treatment and its handset cleaned as its Instructions for Use say
- Diluent and mixed solution checked before each dose and not used if cloudy or with particles
The Cayston label has no boxed warning[1]. Cayston is not used in anyone with a known allergy to aztreonam[1]. Allergic reactions with facial rash, facial swelling and throat tightness were reported in trials, and the label says to stop Cayston if one occurs[1]. The label advises caution in people with a history of allergy to beta-lactam antibiotics such as penicillins, cephalosporins or carbapenems, because cross-reactivity may occur.
People with a known beta-lactam allergy did receive Cayston in trials, and no severe allergic reactions were reported[1]. Bronchospasm, a sudden tightening of the airways, is a known problem with nebulized drugs, and 3% of patients on Cayston had an FEV1 drop of 15% or more right after a dose even after a bronchodilator[1]. The label also notes that people whose FEV1 rose during a 28-day course were sometimes treated for a lung flare when it fell afterward, and asks doctors to compare with the FEV1 measured before Cayston[1].
In the placebo-controlled trials, where 146 patients took 75mg 3 times a day for 28 days, side effects more common on Cayston were cough (54% against 51% on placebo), nasal congestion (16% against 12%), wheezing (16% against 10%), sore throat (12% against 11%), fever (13% against 6%), chest discomfort (8% against 6%), belly pain (7% against 5%) and vomiting (6% against 4%)[1].
Fever was reported more often in children than adults[1]. Joint pain and joint swelling have been reported since approval, with no known frequency[1]. The placebo-controlled trials found no change in how sensitive Pseudomonas was to aztreonam after a 28-day course. Follow-on use of up to 9 courses showed a slight rise in Candida yeast found in sputum[1]. No formal drug interaction studies have been done[1].
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Aztreonam for inhalation solution
The dose for adults and children 7 and older is 1 single-use vial of 75mg aztreonam mixed with 1mL of the supplied saline diluent, breathed in 3 times a day for 28 days, followed by 28 days off Cayston[1]. The dose is not based on weight or adjusted for age, and doses are taken at least 4 hours apart[1]. Cayston is given only with the Altera Nebulizer System, and the label says not to use any other nebulizer or mix other drugs in the Altera handset[1].
A bronchodilator is used before each dose: a short-acting one 15 minutes to 4 hours before, or a long-acting one 30 minutes to 12 hours before[1]. For people on several inhaled treatments, the label's order is bronchodilator, then mucolytics such as Pulmozyme, then Cayston last[1]. Each dose is mixed right before use, poured into the handset and breathed in through the mouthpiece, which typically takes 2 to 3 minutes[1].
The patient information says a missed dose can still be taken, so long as all 3 daily doses stay at least 4 hours apart[1]. Each 28-day kit holds 84 vials and 88 diluent ampules, 4 of them spares in case of spills, in 2 cartons of 14 days each[1]. Kits are kept in the refrigerator at 36°F to 46°F, and once out of the refrigerator they can stay at room temperature up to 77°F for up to 28 days, protected from light, with vials and diluent kept together[1].
Availability and cost
Only available as the brand-name product.
Cayston is sold only as the Gilead brand; as of November 21, 2026 no other finished inhaled aztreonam product appears in the FDA's NDC listings[12]. The label gives no price. Each 28-day kit is used every other month for as long as the doctor continues it, so most of the cost runs through insurance. Gilead's co-pay programs, its patient assistance program and the independent foundations the Cayston Access Program refers people to help with what is left[13][14].
Help paying for Cayston
With private insurance, the drugmaker's copay card can lower what you pay for Cayston. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. None of the 4 charity funds for Cystic Fibrosis were open on November 16, 2026. Without insurance, you can apply to the drugmaker's free medicine program, which sets its own eligibility rules. Pick your insurance below to see which offers fit you.
- Copay help
Cayston and Altera Co-pay Programs: eligible commercially insured patients enrolled in the Cayston Access Program pay no more than $10 per fill, with no monthly limit, capped at 7 fills per calendar year and up to $8,000 a year. Up to $430 a year off an Altera Nebulizer System or Altera replacement unit with a $10 co-pay, up to 2 a year. Not for prescriptions paid in whole or in part by Medicare, Medicaid, VA, DOD, TRICARE or any other state or federally funded program. For residents of the US, Puerto Rico or US territories; the user or enrolling representative must be 18 or older. Gilead may reduce help to $25 per claim under an accumulator adjustment program or end it under a co-pay maximizer.
For: private insurance · source - Free medicine program
Cayston Patient Assistance Program: help for people with no insurance coverage for Cayston who meet income requirements. The page does not publish the income limit.
For: no insurance · source
Good to know: Read on cayston.com/patient-support and the co-pay terms PDF (dated April 6, 2026) on November 21, 2026. Partial because the patient assistance program's income limit is not published. The Cayston Access Program line 1-877-7CAYSTON (1-877-722-9786) is open Monday to Friday, 8 AM to 5 PM Eastern; enrolling is not required to get Cayston. The program verifies benefits, helps with prior authorization and appeals, refers prescriptions to a specialty pharmacy, and refers people who do not qualify for co-pay help to independent foundations such as The HealthWell Foundation, The Assistance Fund and Patient Services, Inc., including for the Altera nebulizer.
Charity funds for Cystic Fibrosis
- From a charity · The Assistance FundCystic Fibrosis fundWaitlist
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
Access and eligibility
Approved to improve breathing symptoms in people with cystic fibrosis who have Pseudomonas aeruginosa[1]. The label says safety and effectiveness have not been established in children under 7, in people with FEV1 below 25% or above 75% of predicted, or in people colonized with Burkholderia cepacia[1]. The label says Cayston should be used only in people with cystic fibrosis known to have Pseudomonas aeruginosa in the lungs, to limit drug-resistant bacteria[1]. Cayston is not used in anyone with a known allergy to aztreonam[1]. The trials did not include people 65 or older, and no dose change is needed for kidney problems because so little drug reaches the blood[1].
Source: Cayston patient support
Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.
Clinical trial results
The label rests on a 28-day randomized, double-blind trial of 164 people 7 and older with cystic fibrosis, Pseudomonas aeruginosa and FEV1 of 25-75% of predicted, while the published paper lists ages 6 and older. The participants' average age was 30 and their average FEV1 55% of predicted, and none had taken antibiotics in the 28 days before[1].
Participants took Cayston 75mg or placebo 3 times a day through the Altera nebulizer, after a bronchodilator, on top of standard care[1]. Breathing symptoms on a patient questionnaire, the main goal, improved more on Cayston than placebo at day 28, in both adults and children, though the gain was substantially smaller in adults. A smaller difference remained 2 weeks after treatment ended[1].
FEV1 was 10% higher on Cayston than placebo at day 28 (95% CI 6-14%), with similar gains in adults and children, and the gap had narrowed to 6% (95% CI 2-9%) 2 weeks later[1]. The trial, AIR-CF1 (NCT00112359), was published in Chest in 2009 by Retsch-Bogart and colleagues[3][6]. A second placebo-controlled trial, AIR-CF2 (NCT00104520), enrolled 211 people who had used inhaled tobramycin often, gave everyone 28 days of tobramycin solution first, then Cayston or placebo for 28 days.
The median time until more anti-Pseudomonas antibiotics were needed was 92 days on Cayston against 71 on placebo (McCoy and colleagues, American Journal of Respiratory and Critical Care Medicine, 2008)[4][7]. An open-label Phase 3 trial sponsored by Gilead (NCT00757237) randomized 273 people 6 and older to 3 courses of Cayston 75mg 3 times a day or tobramycin inhalation solution 300mg twice a day, each 28 days on and 28 off[5][8].
After 1 course, FEV1 had risen by an average relative 8.35% on Cayston against 0.55% on tobramycin, and across 3 courses the average change was 2.05% against minus 0.66%. The authors reported statistical superiority for Cayston on lung function, along with fewer hospital stays for breathing problems and fewer breathing events needing extra anti-Pseudomonas antibiotics (Assael and colleagues, Journal of Cystic Fibrosis, 2013)[5].
Development history
Gilead developed aztreonam lysine for inhalation, called AZLI in its trials, as an inhaled form of the older injected antibiotic aztreonam. The FDA approved Cayston on February 22, 2010 under NDA 050814 as a new dosage form[2]. The prescribing text was last revised in November 2019, matching a labeling supplement the FDA approved on November 20, 2019[1][2].
The label's pediatric section says 55 patients under 18 received Cayston in the placebo-controlled trials, and that use under 7 has not been established[1]. As of November 21, 2026, Cayston from Gilead is the only finished inhaled aztreonam product in the FDA's NDC listings, and the other finished aztreonam products listed are injections[12].
Explore Cystic Fibrosis trials
Other Cystic Fibrosis treatments
Common questions about Aztreonam for inhalation solution
▸What is Aztreonam for inhalation solution (Cayston)?
An antibiotic breathed in through the Altera nebulizer 3 times a day for 28 days, then stopped for 28 days, for people with cystic fibrosis who have Pseudomonas aeruginosa bacteria in their lungs[1]. Cayston is approved to improve breathing symptoms in these patients, and the FDA first approved it on February 22, 2010[1][2]. The label says safety and effectiveness have not been established in children under 7, in people whose FEV1 is below 25% or above 75% of predicted, or in people colonized with Burkholderia cepacia[1]. Its label has no boxed warning[1].
▸How does Aztreonam for inhalation solution work?
Many people with cystic fibrosis carry Pseudomonas aeruginosa, a bacterium that settles in the thick mucus of the airways and keeps coming back. Aztreonam is an antibiotic that attacks Gram-negative bacteria such as Pseudomonas, according to the Cayston label[1]. Aztreonam binds penicillin-binding proteins, which the bacteria use to build their cell walls, and that stops the wall from forming and kills the cell[1]. The label says aztreonam keeps working in the presence of cystic fibrosis lung secretions[1]. Aztreonam belongs to the monobactams, whose single-ring core is built differently from penicillins, cephalosporins and carbapenems, the beta-lactam antibiotics[1]. Breathing it in puts the drug where the bacteria live. Sputum held an average of 726mcg/g of aztreonam 10 minutes after the first 75mg dose, while blood levels peaked near 0.59mcg/mL, against about 54mcg/mL after a 500mg injection[1]. About 10% of an inhaled dose leaves the body unchanged in urine, and the half-life in blood is about 2.1 hours[1]. Cayston treats the infection and does not change the faulty CFTR protein that causes cystic fibrosis.
▸What are the side effects of Aztreonam for inhalation solution?
The Cayston label has no boxed warning[1]. Cayston is not used in anyone with a known allergy to aztreonam[1]. Allergic reactions with facial rash, facial swelling and throat tightness were reported in trials, and the label says to stop Cayston if one occurs[1]. The label advises caution in people with a history of allergy to beta-lactam antibiotics such as penicillins, cephalosporins or carbapenems, because cross-reactivity may occur. People with a known beta-lactam allergy did receive Cayston in trials, and no severe allergic reactions were reported[1]. Bronchospasm, a sudden tightening of the airways, is a known problem with nebulized drugs, and 3% of patients on Cayston had an FEV1 drop of 15% or more right after a dose even after a bronchodilator[1]. The label also notes that people whose FEV1 rose during a 28-day course were sometimes treated for a lung flare when it fell afterward, and asks doctors to compare with the FEV1 measured before Cayston[1]. In the placebo-controlled trials, where 146 patients took 75mg 3 times a day for 28 days, side effects more common on Cayston were cough (54% against 51% on placebo), nasal congestion (16% against 12%), wheezing (16% against 10%), sore throat (12% against 11%), fever (13% against 6%), chest discomfort (8% against 6%), belly pain (7% against 5%) and vomiting (6% against 4%)[1]. Fever was reported more often in children than adults[1]. Joint pain and joint swelling have been reported since approval, with no known frequency[1]. The placebo-controlled trials found no change in how sensitive Pseudomonas was to aztreonam after a 28-day course. Follow-on use of up to 9 courses showed a slight rise in Candida yeast found in sputum[1]. No formal drug interaction studies have been done[1].
▸How is Aztreonam for inhalation solution taken?
The dose for adults and children 7 and older is 1 single-use vial of 75mg aztreonam mixed with 1mL of the supplied saline diluent, breathed in 3 times a day for 28 days, followed by 28 days off Cayston[1]. The dose is not based on weight or adjusted for age, and doses are taken at least 4 hours apart[1]. Cayston is given only with the Altera Nebulizer System, and the label says not to use any other nebulizer or mix other drugs in the Altera handset[1]. A bronchodilator is used before each dose: a short-acting one 15 minutes to 4 hours before, or a long-acting one 30 minutes to 12 hours before[1]. For people on several inhaled treatments, the label's order is bronchodilator, then mucolytics such as Pulmozyme, then Cayston last[1]. Each dose is mixed right before use, poured into the handset and breathed in through the mouthpiece, which typically takes 2 to 3 minutes[1]. The patient information says a missed dose can still be taken, so long as all 3 daily doses stay at least 4 hours apart[1]. Each 28-day kit holds 84 vials and 88 diluent ampules, 4 of them spares in case of spills, in 2 cartons of 14 days each[1]. Kits are kept in the refrigerator at 36°F to 46°F, and once out of the refrigerator they can stay at room temperature up to 77°F for up to 28 days, protected from light, with vials and diluent kept together[1].
▸Is Aztreonam for inhalation solution FDA approved?
Yes. The FDA approved Cayston on February 22, 2010, to improve breathing symptoms in people with cystic fibrosis who have Pseudomonas aeruginosa.
Age: the label says safety and effectiveness have not been established under age 7.
Lung function: it has not been established in people with FEV1 below 25% or above 75% of predicted, or in people colonized with Burkholderia cepacia.
Generic: as of November 21, 2026, no other finished inhaled aztreonam product appears in the FDA's NDC listings.
Source: Cayston prescribing information
▸What is the Cayston dose and schedule?
The label dose is 1 vial of 75mg mixed with 1mL of the supplied diluent, breathed in 3 times a day for 28 days, then 28 days off[1].
Spacing: doses are taken at least 4 hours apart.
Same for all ages: the dose is not based on weight or adjusted for age in people 7 and older.
Missed dose: the patient information says all 3 daily doses can still be taken as long as they stay at least 4 hours apart.
Kit: each 28-day kit holds 84 vials and 88 diluent ampules, including 4 spares.
Source: Cayston prescribing information
▸What nebulizer is used with Cayston, and in what order with other inhaled medicines?
Cayston is given only with the Altera Nebulizer System, and the label says not to use any other nebulizer[1].
Bronchodilator first: a short-acting one 15 minutes to 4 hours before, or a long-acting one 30 minutes to 12 hours before.
Order: bronchodilator, then mucolytics such as Pulmozyme, then Cayston last.
Not mixed: no other drugs go into the Altera handset with Cayston.
Time: a dose typically takes 2 to 3 minutes.
Source: Cayston prescribing information
▸What are the side effects of Cayston?
In the placebo-controlled trials, cough, nasal congestion, wheezing, sore throat, fever, chest discomfort, belly pain and vomiting were more common on Cayston than placebo[1].
Fever: 13% against 6% on placebo, and more often reported in children.
Wheezing: 16% against 10%.
Bronchospasm: 3% had an FEV1 drop of 15% or more right after a dose.
Allergy: facial rash, facial swelling and throat tightness were reported, and Cayston is not used with a known aztreonam allergy.
Source: Cayston prescribing information
▸Has Cayston been compared with inhaled tobramycin (TOBI)?
Yes, in 1 open-label Phase 3 trial sponsored by Gilead that compared Cayston with tobramycin inhalation solution over 3 on and off courses in 273 people 6 and older[5].
Lung function: FEV1 rose an average relative 8.35% after 1 course of Cayston against 0.55% on tobramycin, and the authors reported statistical superiority for Cayston across 3 courses.
Flares: the Cayston group had fewer hospital stays for breathing problems and fewer events needing extra anti-Pseudomonas antibiotics.
Open-label: patients and doctors knew which drug was given.
Label: the Cayston label describes only its placebo-controlled trial.
▸Does Cayston need to be refrigerated?
Yes. Cayston vials and diluent ampules are stored in the refrigerator at 36°F to 46°F until needed[1].
Room temperature: once out of the refrigerator, they can stay at up to 77°F for up to 28 days, and are not used after more than 28 days at room temperature.
Together: vials and diluent are kept together and protected from light.
Mixing: each dose is mixed right before use, and one that is cloudy or has particles is not used.
Source: Cayston prescribing information
▸Is there help paying for Cayston?
Gilead's Cayston Access Program offers co-pay help for commercially insured patients and a patient assistance program for people with no insurance coverage for Cayston who meet income requirements[13].
Co-pay: no more than $10 per fill, capped at 7 fills and $8,000 a year; not for Medicare, Medicaid, VA, DOD, TRICARE or other government-funded plans.
Altera: up to $430 a year off up to 2 Altera nebulizer systems or replacement units, with a $10 co-pay.
Foundations: the program refers people to independent foundations such as The HealthWell Foundation, The Assistance Fund and Patient Services, Inc.
Phone: 1-877-722-9786, Monday to Friday, 8 AM to 5 PM Eastern time.
Source: Cayston patient support
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- Gilead Sciences, Inc. via DailyMed · 2025-12-01. CAYSTON (aztreonam for inhalation solution). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=67300ca3-8c53-4ce4-8e86-2c03be1f9b8a
- U.S. Food and Drug Administration (openFDA) · 2010-02-22. CAYSTON approval history, NDA 050814 (openFDA drugsfda record). https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA050814
- Chest 2009;135(5):1223-1232 (PubMed) · 2009-05. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.. https://pubmed.ncbi.nlm.nih.gov/19420195/
- Am J Respir Crit Care Med 2008;178(9):921-8 (PubMed) · 2008-11-01. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.. https://pubmed.ncbi.nlm.nih.gov/18658109/
- J Cyst Fibros 2013;12(2):130-40 (PubMed) · 2013-03. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.. https://pubmed.ncbi.nlm.nih.gov/22985692/
- ClinicalTrials.gov. International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa. https://clinicaltrials.gov/study/NCT00112359
- ClinicalTrials.gov. Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa. https://clinicaltrials.gov/study/NCT00104520
- ClinicalTrials.gov. Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa. https://clinicaltrials.gov/study/NCT00757237
- Viatris Specialty LLC via DailyMed · 2025-11-15. TOBI (tobramycin inhalation solution). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a3c3871-1d3a-44d6-8be3-526b30123ef7
- Genentech, Inc. via DailyMed · 2025-12-17. PULMOZYME- dornase alfa solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8c78a7e-ff99-48f3-8952-643ec2ea0f86
- Vertex Pharmaceuticals Incorporated via DailyMed · 2026-06-22. TRIKAFTA (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f354423a-85c2-41c3-a9db-0f3aee135d8d
- U.S. Food and Drug Administration (openFDA) · 2026-11-21. NDC directory search for aztreonam. https://api.fda.gov/drug/ndc.json?search=generic_name:aztreonam&limit=50
- Gilead Sciences. Patient Support | CAYSTON® (aztreonam for inhalation solution). https://www.cayston.com/patient-support
- Gilead Sciences · 2026-04-06. Gilead CAYSTON Co-pay Savings Program and ALTERA Co-pay Savings Program Terms and Conditions. https://www.cayston.com/-/media/affinity/cayston/pdfs/cayston-and-altera-co-pay-savings-tscs.pdf